NCT04716569

Evaluation of Ivermectin Mucoadhesive Nanosuspension as Nasal Spray in Management of Early Covid-19

Faculty of Medicine ,South Valley University

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 150 (estimated)
• Sponsor: South Valley University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Ivermectin showed a strong viricidal effect upon covid19 virus in vitro as proved by many authors according to many studies , covid virus stay in postnasal space for 4 days before starting general manifestation, so ivermectin mucoadhesive nanosuspension sprayed inside the nose and post nasal space may help in early management of covid19 and may play a great rule in prophylaxis as well

Detailed description

150 patient with early covid is devided into two groups first group will receive regular protocol of drugs second group will receive ivermectin nasal spray in addition to regular protocl of drugs

Conditions

• Covid19

Interventions

Type	Name	Description
DRUG	intranasal ivermectin spray	usage of ivermectin as intranasal spray for treating early covid patiens

Timeline

• Start date: 2021-01-20
• Primary completion: 2021-02-20
• Completion: 2021-03-20
• First posted: 2021-01-20
• Last updated: 2021-03-17

Locations

1 site across 1 country: Egypt